Multi-targeted TKIs such as afatinib and dacominitib have been studied in RM SCCHN
Multi-targeted TKIs such as afatinib and dacominitib have been studied in RM SCCHN. one area that has helped improve results with this disease. Anti-EGFR centered therapies have been shown to improve overall survival and mitigate the significant toxicities incurred from standard radiation, chemotherapy, and/or medical options. Cetuximab, probably the most well-studied anti-EGFR monoclonal antibody, offers […]